{"id":215,"date":"2014-07-01T10:04:00","date_gmt":"2014-07-01T14:04:00","guid":{"rendered":"http:\/\/jaydub.cms-devl.bu.edu\/aodhealth\/2014\/01\/01\/acamprosate-and-naltrexone-similar-efficacy-for-reducing-return-to-drinking\/"},"modified":"2017-01-31T11:45:06","modified_gmt":"2017-01-31T16:45:06","slug":"acamprosate-and-naltrexone-similar-efficacy-for-reducing-return-to-drinking","status":"publish","type":"post","link":"https:\/\/www.bu.edu\/aodhealth\/2014\/07\/01\/acamprosate-and-naltrexone-similar-efficacy-for-reducing-return-to-drinking\/","title":{"rendered":"Acamprosate and Naltrexone:  Similar Efficacy for Reducing Return to Drinking"},"content":{"rendered":"<div class=\"research-summary-body\">\n                    <!-- InstanceBeginEditable name=\"contents\" --><\/p>\n<p>Most  people with alcohol use disorders do not receive treatment, and very few  receive medication treatment. Investigators systematically searched the  literature to identify double-blind randomized trials of medications for adult  outpatients with alcohol dependence (non-randomized studies of health outcomes  and adverse effects were included); 123 studies with 22,803 participants were  included in the report and 95 in meta-analyses.<\/p>\n<ul>\n<li>Acamprosate  and naltrexone both reduced return to any drinking (numbers needed to treat, 12  and 20, respectively), and there were no differences in head to head  comparisons. Naltrexone reduced heavy drinking.<\/li>\n<li>Acamprosate  studies with the lowest risk of bias found no efficacy for the medication.<\/li>\n<li>Topiramate  and nalmefene both reduced several drinking outcomes.<\/li>\n<li>There  was insufficient evidence for improvements in health outcomes for any  medication.<\/li>\n<li>Naltrexone  was associated with dizziness, nausea, and vomiting (number needed to harm  [NNH], 16, 9, and 24, respectively).<\/li>\n<li>Acamprosate  was associated with anxiety, diarrhea, and vomiting (NNH, 7, 11, and 42,  respectively).<\/li>\n<li>Topiramate  was associated with cognitive dysfunction, paresthesias, and taste abnormalities  (NNH, 12, 4, and 7, respectively).<\/li>\n<li>Nalmefene  was associated with dizziness, headache, insomnia, nausea, and vomiting (NNH,  7, 26, 10, 7, and 17, respectively).<\/li>\n<\/ul>\n<p><!-- InstanceEndEditable --><\/p>\n<div class=\"research-summary-footnotes-1\">\n\t\t\t\t\t\t<!-- InstanceBeginEditable name=\"footnotes-1\" --><!-- InstanceEndEditable -->\n\t\t\t\t\t<\/div>\n<h2 class=\"research-summary-comments\">Comments:<\/h2>\n<p>\t\t\t\t\t<!-- InstanceBeginEditable name=\"comments\" -->There  are a few caveats to consider when interpreting this report. Firstly,  disulfiram was not found to have efficacy, but placebo-controlled trials are  not optimal for testing the efficacy of a medication that requires that patients  know they are taking it. Studies of supervised oral disulfiram have  demonstrated efficacy. Secondly, most studies provided psychosocial counseling,  which may be necessary for better treatment outcomes, though not easily  delivered in primary care settings. Lastly, the medications have side effects  and have not been shown to affect outcomes beyond consumption. Nonetheless, medications  for alcohol use disorders have modest efficacy for reducing drinking in people  with moderate to severe alcohol use disorders.<!-- InstanceEndEditable --><br \/>\n                    <cite><br \/>\n\t\t\t\t\t\t<!-- InstanceBeginEditable name=\"name\" -->Richard Saitz, MD, MPH <!-- InstanceEndEditable --><br \/>\n\t\t\t\t\t<\/cite><\/p>\n<div class=\"research-summary-footnotes\">\n\t\t\t\t\t<!-- InstanceBeginEditable name=\"footnotes\" --><!-- InstanceEndEditable -->\n\t\t\t\t\t<\/div>\n<h2>Reference:<\/h2>\n<p>\t\t\t\t\t<!-- InstanceBeginEditable name=\"reference\" -->Jonas  DE, Amick HR, Feltner C, et al. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24825644\">Pharmacotherapy for adults with alcohol use  disorders in outpatient settings. a systematic review and meta-analysis.<\/a> <em>JAMA<\/em>. 2014;311:1889\u20131900. <!-- InstanceEndEditable -->\n\t\t\t\t<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Most people with alcohol use disorders do not receive treatment, and very few receive medication treatment. Investigators systematically searched the literature to identify double-blind randomized trials of medications for adult outpatients with alcohol dependence (non-randomized studies of health outcomes and adverse effects were included); 123 studies with 22,803 participants were included in the report and [&hellip;]<\/p>\n","protected":false},"author":11272,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[25],"tags":[76],"_links":{"self":[{"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/posts\/215"}],"collection":[{"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/users\/11272"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/comments?post=215"}],"version-history":[{"count":1,"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/posts\/215\/revisions"}],"predecessor-version":[{"id":2134,"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/posts\/215\/revisions\/2134"}],"wp:attachment":[{"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/media?parent=215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/categories?post=215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/tags?post=215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}